Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023 March 25, 2024
Engrail closes $157M series B, fueled by investors’ renewed interest in neuropsychiatry March 19, 2024
Engrail Therapeutics Closes Oversubscribed $157M Series B Financing Round to Advance the Development of Transformational Therapies March 19, 2024
KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey March 19, 2024
KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update March 12, 2024